PTPRCAP and neoplasm: Consistent with the mRNA findings, immunohistochemical analysis demonstrated a substantially lower positive expression rate of PTPRCAP protein in tumor tissues (22.22%, 10/45) relative to paracancerous tissues (93.33%, 42/45), with a concomitantly reduced immunoreactivity score (IRS) (P < 0.0001, Fig 2).